Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334505 | 0.90 | KDM4E (0.55) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL162660 | 0.82 | MEN1 (0.56) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL9414571 | 0.81 | KDM4E (0.65) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL28658509 | 0.80 | CYP3A4 (0.61) | KDM4EMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL28670802 | 0.78 | MEN1 (0.60) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL5594628 | 0.78 | SRC (0.59) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL18831783 | 0.78 | SRC (0.48) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4047218 | 0.77 | KDM4E (0.61) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL14577795 | 0.77 | KDM4E (0.61) | KDM4EMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL1108327 | 0.77 | MEN1 (0.65) | KDM4EMEN1KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | TP53, MDM4, MDM2 | KDM4E 2728/4885MEN1 395/4885KMT2A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.